The research confirmed no unusual threats, which indicated that it could be safely administered in a medical research context. Afterwards, Dr. Charles Grob requested authorization to additional research the compound with most cancers individuals, but was denied by the FDA 2 times.The primary report with the synthesis of copyright in the peer-review